在 2026 年国际消费电子展（ CES ）上， Neurable 宣布与惠普旗下游戏品牌 HyperX 达成战略合作，计划共同开发 业界首款集成神经技术的游戏耳机 。 这 款新型可穿戴设备将结合人工智能与 非侵入式传感器 ，在游戏过程中实时解读脑电信号（ EEG ），并把玩家的神经活动转化为可量化、可用于训练与优化 的表现指标。 与传统脑电监测设备常见的笨重头盔式形态不同，该产品采用 Neurable 的 微型脑机接口（ BCI ）技术 ，可以在不牺牲佩戴体验的前提下嵌入 HyperX 的耳 机结构中，做到 更纤薄、更轻量、外观更 " 隐形 " ，从而更贴近玩家日常使用场景。 Neurable 同时展示了 " 实时脑部活动洞察 " 对提升玩家表现的潜在价值。在一项面向 半职业电竞选手 的初步研究中， Neurable 的神经反馈系统 Prime 在第 一人称射击（ FPS ）训练任务中带来了可观改进：参与者整体表现为 反应更快、命中率更高、击中目标数量更多 。平均来看，反应时间缩短 43 毫秒 ，命中 率提升 0.53% ，并在射击心理测试中 额外击中近 9 个目标 。 在 大学及职业电竞选手 群体中，提升 ...

编辑丨王多鱼 排版丨水成文 深圳医学科学院 （Shenzhen Medical Academy of Research and Translation，SMART） ， 是一家为 未来医学科学开辟新道路的机构。SMART 致力于探索最能激发原始创新的新机制，同时培养一支能够应对 紧迫挑战的顶尖人才团队。在 SMART，将科学技术转化为全民健康是我们工作的核心。SMART 采用全过 程方法，不断突破生物医学研究的界限， 打通临床医学、基础研究、产业转化等环节之间的障碍 。扎根深 圳，SMART 敢于梦想，致力于将深圳建设成为人才汇聚的智慧之城和全球生物医学科学的强大力量。 Collaboration & Facility Support 职位概述 深圳医学科学院 i-BRAIN 纳米制造设施 是一个世界级的国际设施，支持前沿的 脑机接口 （BCI） 和 神经 技术 研究。目前正在寻找积极进取的 高级工程师 加入团队，有机会领导四个技术领域之一： 高级工程师将在其专业领域主导工艺开发、工具操作和用户培训，同时为设施运营提供跨职能支持。该职 位提供了在纳米制造前沿工作的机会，与科学家、临床医生和行业合作伙伴合作，推 ...

国际大会的成功举办，进一步彰显了莫斯科作为全球商务旅游与会奖产业重要枢纽的国际地位。大会汇 聚了来自金砖国家及"全球南方"37个国家的行业代表和专业人士，国际参与度显著提升。与上一届相 比，本届大会参会规模实现翻倍，吸引了超过2500名与会嘉宾。大会采用多元化活动形式，围绕会奖旅 游目的地发展、商务活动成效评估、体验经济发展趋势以及神经技术在行业中的未来应用等前沿议题展 开深入交流与探讨，并创下历届大会商务洽谈数量新高，为推动全球会展与商务旅游领域的交流合作搭 建了高效务实的平台。 中国市场在本届大会中表现尤为活跃。2025年全球会展大会(MGMC)共吸引来自中国的41位会奖旅游行 业代表参会，充分体现了中国企业对国际专业交流平台的高度重视，以及对莫斯科作为会奖目的地的浓 厚兴趣。在同期举办的展览展示区，中国国家旅游办事处及香港旅游发展局作为参展机构亮相，向与会 嘉宾全面推介各自的旅游资源与产品，进一步深化了中外旅游及会奖产业的交流与合作。 汇聚来自37个国家的国际嘉宾 国际商务旅游论坛——莫斯科全球会奖大会(Meet Global MICE Congress，MGMC)成果在莫斯科正式发 布。大会于12月1 ...

新华社巴黎11月5日电（记者罗毓）联合国教科文组织会员国5日正式通过首个面向全球的神经技术伦理 准则性框架《神经技术伦理问题建议书》，其确立的关键保障措施将确保神经技术用于改善最需帮助人 群的生活，同时避免损害人权。 官方公报说，神经技术包括可直接与神经系统交互以测量、调节或刺激神经系统的工具。该技术在医疗 领域前景广阔：脑深部刺激可缓解抑郁症、帕金森病症状；脑机接口让残障者能通过意念控制假肢或沟 通交流。 尽管神经技术的医疗应用已受严格监管，但在其他领域仍普遍缺乏规范。许多消费者通过智能头带、耳 机等日常设备使用该技术，而这些设备利用神经数据监测心率、压力或睡眠，采集的高敏感数据可能泄 露思想、情绪、反应，并在未经同意情况下被共享。《建议书》呼吁各国政府确保神经技术的包容性和 可负担性，同时建立保护人类思想不可侵犯的防护机制。 《建议书》还指出神经技术的其他风险，尤其建议把该技术在大脑尚处发育阶段的儿童和青少年中的应 用限制在治疗用途。《建议书》还警示在职场中使用神经技术监测生产力或建立员工数据档案的行为， 强调必须取得明确同意并确保信息透明。 联合国教科文组织大会正在乌兹别克斯坦撒马尔罕召开，该规范将于1 ...

Core Viewpoint - ONWARD Medical N.V. has received FDA approval for an investigational device exemption for its ARC-IM System, enabling the initiation of the Empower BP pivotal study to evaluate the safety and efficacy of its implantable spinal stimulation system for managing blood pressure instability after spinal cord injury (SCI) [2][7]. Group 1: Study Details - The Empower BP study is the second global pivotal study for ONWARD and the first to assess the ARC-IM System, involving approximately 20 leading neurorehabilitation and neurosurgical centers across the US, Canada, and Europe, with patient enrollment expected by year-end [3][7]. - The study will focus on participants with spinal cord injuries at levels C2-T6, with injury severities of AIS A-D, and those experiencing chronic orthostatic hypotension and episodes of autonomic dysreflexia [3]. Group 2: Market Need and Impact - Over 50% of individuals with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe, which can threaten neurological recovery and negatively impact cardiovascular health and quality of life [4][5]. - Addressing blood pressure instability is critical for improving long-term outcomes for SCI patients, as it is a significant but often unrecognized complication that can lead to increased cardiovascular disease risk [5][8]. Group 3: Technology Overview - The ARC-IM System is an implanted neuromodulation platform designed to deliver targeted spinal cord stimulation, specifically aimed at managing blood pressure instability in SCI patients [5][9]. - The system includes the ONWARD Neurostimulator and the ARC-IM Thoracic Lead, which is optimized for placement in the thoracic spinal cord's "Hemodynamic Hotspot," a location identified through research partnerships [5][6]. Group 4: Previous Results and Future Outlook - In December 2022, ONWARD announced positive interim clinical results from feasibility studies showing improved blood pressure regulation and hemodynamic stability after SCI, with participants reporting enhanced well-being and reduced symptoms of orthostatic hypotension [6]. - The FDA has awarded ONWARD one of its 10 Breakthrough Device Designations for the ARC-IM System, indicating its potential to address significant unmet medical needs and providing regulatory and reimbursement advantages [8].

Core Insights - The article highlights the significant advancements and investments in the brain-computer interface (BCI) industry, particularly in China, where policies and clinical trials are paving the way for commercialization [1][16][26]. Group 1: Industry Developments - The BCI technology has been recognized as one of the ten landmark products for future industries, with specific pricing standards established for medical services related to BCI [1]. - Several startups in the BCI space are transitioning from laboratory research to clinical trials, with hospitals across the country beginning to establish clinical research wards for various neurological conditions [1][16]. - The year 2025 is anticipated to be a pivotal year for the BCI industry in China, marking the beginning of large-scale clinical trials for fully implanted micro-systems [1][15]. Group 2: Investment Trends - Investment in the BCI sector surged in 2022, with notable funding rounds, including Neuralink's $650 million financing, which raised its valuation to $9 billion [4]. - New investors from the TMT medical sector are entering the BCI market, driven by optimism about new technologies and the potential for high returns [5][6]. - The influx of capital and supportive policies have encouraged major hospitals to participate in BCI research and development [6][26]. Group 3: Challenges and Perspectives - Companies in the BCI field face significant challenges, including the need for continuous funding to support clinical trials and product development [12][22]. - The industry is experiencing a "淘汰赛" (elimination race), where companies must demonstrate clinical progress and secure funding to survive [27]. - There is a growing concern among BCI entrepreneurs about the sustainability of their businesses amid rising competition and the need for substantial investment [22][29]. Group 4: Clinical Applications and Future Outlook - BCI technology has the potential to treat various neurological disorders, with a focus on developing systems that can provide real-time monitoring and support during surgeries [46][47]. - The article emphasizes the importance of practical applications and the need for BCI products to prove their effectiveness in clinical settings [50][52]. - The long-term vision for BCI technology is to create high-performance medical devices that can significantly improve the quality of life for patients with neurological conditions [52][53].